TransMedics Group, Inc. (NASDAQ:TMDX) shares gapped down prior to trading on Monday . The stock had previously closed at $31.74, but opened at $30.76. TransMedics Group shares last traded at $30.54, with a volume of 104 shares trading hands.
Several research firms have weighed in on TMDX. Cowen restated a “buy” rating and issued a $49.00 price objective on shares of TransMedics Group in a research report on Friday, June 18th. Oppenheimer began coverage on shares of TransMedics Group in a research report on Thursday, July 8th. They issued a “buy” rating and a $49.00 price objective for the company. Finally, Zacks Investment Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, TransMedics Group presently has a consensus rating of “Hold” and a consensus target price of $43.17.
The firm’s 50-day moving average price is $30.25 and its 200 day moving average price is $30.85. The company has a debt-to-equity ratio of 0.39, a quick ratio of 8.09 and a current ratio of 8.96. The company has a market cap of $858.83 million, a price-to-earnings ratio of -28.26 and a beta of 2.01.
In other news, CFO Stephen Gordon sold 10,000 shares of the business’s stock in a transaction on Thursday, June 17th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the chief financial officer now owns 10,000 shares of the company’s stock, valued at $300,000. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP John F. Carey sold 1,680 shares of the business’s stock in a transaction on Thursday, July 1st. The stock was sold at an average price of $33.65, for a total transaction of $56,532.00. The disclosure for this sale can be found here. Insiders have sold a total of 46,352 shares of company stock worth $1,566,043 in the last three months. 10.30% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in the company. Total Clarity Wealth Management Inc. bought a new stake in TransMedics Group during the first quarter worth about $27,000. Lazard Asset Management LLC acquired a new stake in shares of TransMedics Group during the 1st quarter worth approximately $33,000. Eaton Vance Management acquired a new stake in shares of TransMedics Group during the 1st quarter worth approximately $54,000. O Shaughnessy Asset Management LLC bought a new position in shares of TransMedics Group in the 1st quarter worth $55,000. Finally, Point72 Hong Kong Ltd lifted its holdings in shares of TransMedics Group by 2,245.5% in the 1st quarter. Point72 Hong Kong Ltd now owns 1,548 shares of the company’s stock worth $64,000 after purchasing an additional 1,482 shares in the last quarter. 67.99% of the stock is owned by institutional investors.
About TransMedics Group (NASDAQ:TMDX)
TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Recommended Story: How much money do you need to begin day trading?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.